Altering the course of schizophrenia: progress and perspectives

Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger

doi:10.1038/nrd.2016.28

Back

Altering the course of schizophrenia: progress and perspectives

Journal article

Open access

Peer reviewed

Altering the course of schizophrenia: progress and perspectives

Mark J Millan, Annie Andrieux, George Bartzokis, Kristin Cadenhead, Paola Dazzan, Paolo Fusar-Poli, Jürgen Gallinat, Jay Giedd, Dennis R Grayson, Markus Heinrichs, …

Nature reviews. Drug discovery, Vol.15(7), pp.485-515

2016-07

DOI: https://doi.org/10.1038/nrd.2016.28

PMID: 26939910

Abstract

Schizophrenia - drug therapy

Schizophrenia - diagnosis

Antipsychotic Agents - therapeutic use

Humans

Despite a lack of recent progress in the treatment of schizophrenia, our understanding of its genetic and environmental causes has considerably improved, and their relationship to aberrant patterns of neurodevelopment has become clearer. This raises the possibility that 'disease-modifying' strategies could alter the course to - and of - this debilitating disorder, rather than simply alleviating symptoms. A promising window for course-altering intervention is around the time of the first episode of psychosis, especially in young people at risk of transition to schizophrenia. Indeed, studies performed in both individuals at risk of developing schizophrenia and rodent models for schizophrenia suggest that pre-diagnostic pharmacotherapy and psychosocial or cognitive-behavioural interventions can delay or moderate the emergence of psychosis. Of particular interest are 'hybrid' strategies that both relieve presenting symptoms and reduce the risk of transition to schizophrenia or another psychiatric disorder. This Review aims to provide a broad-based consideration of the challenges and opportunities inherent in efforts to alter the course of schizophrenia.

Files and links (1)

url

https://doi.org/10.1038/nrd.2016.28View

Published (Version of record) Open

Metrics

27 Record Views

250 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.21 Psychiatry; 1.21.24 Schizophrenia
Web Of Science research areas: Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Altering the course of schizophrenia: progress and perspectives
Creators: Mark J Millan - Pole for Innovation in Neuropsychiatry, Institut de Recherche (IDR) Servier, 78290 Croissy-sur-Seine, France
Annie Andrieux - Inserm, U836, Physiopathologie du cytosquelette, Grenoble Institut des Neurosciences, 38700 Grenoble, France
George Bartzokis - Department of Psychiatry, The David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, USA
Kristin Cadenhead - Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA
Paola Dazzan - Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
Paolo Fusar-Poli - Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
Jürgen Gallinat - Psychiatrische Universitätsklinik der Charité im Saint Hedwig-Krankenhaus, 10115 Berlin, Germany
Jay Giedd - Child Psychiatry Branch, Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA
Dennis R Grayson - Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA
Markus Heinrichs - Freiburg Brain Imaging Center, University of Freiburg, 79106 Freiburg, Germany
René Kahn - Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
Marie-Odile Krebs - Service de Psychiatrie, Centre Hospitalier Sainte-Anne, 75014 Paris, France
Marion Leboyer - Inserm, U955, Psychopathologie et génétique des maladies psychiatriques, 94000 Créteil, Paris, France
David Lewis - Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Oscar Marin - Medical Research Council (MRC) Centre for Developmental Neurobiology, King's College London, London SE1 1UL, UK
Philippe Marin - Le Centre National de la Recherche Scientifique (CNRS), UMR-5203, Institut de Génomique Fonctionnelle, F-34000 Montpellier, France
Andreas Meyer-Lindenberg - Central Institute for Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, Mannheim, Germany
Patrick McGorry - Orygen, the National Centre of Excellence in Youth Mental Health, Parkville, Victoria 3052, Australia
Philip McGuire - Department of Psychosis Studies, Institute of Psychiatry, King's College London, London SE5 8AF UK
Michael J Owen - Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK
Paul Patterson - Institute of Neuroscience and Psychology, University of Glasgow, Glasgow G12 8QB, UK
Akira Sawa - Johns Hopkins University Schools of Medicine and Public Health, Baltimore, Maryland MD21205, USA
Michael Spedding - Spedding Research Solutions SARL, 78110 le Vesinet, France
Peter Uhlhaas - Institute of Neuroscience and Psychology, University of Glasgow, Glasgow G12 8QB, UK
Flora Vaccarino - Child Study Center, Yale School of Medicine, New Haven, Connecticut 06519, USA
Claes Wahlestedt - Department of Psychiatry and Behavioural Sciences, University of Miami Miller School of Medicine, Miami 33136, Florida, USA
Daniel Weinberger - Lieber Institute for Brain Development, Johns Hopkins University School of Medicine, Baltimore, Maryland MD21205, USA
Publication Details: Nature reviews. Drug discovery, Vol.15(7), pp.485-515
Publisher: England
Grant note: MR/L010305/1 / Medical Research Council MR/N026063/1 / Medical Research Council G0800509 / Medical Research Council
Academic Unit: Miller School of Medicine; UMMG Dept of Psychiatry & Behavioral Sciences
Language: English
Resource Type: Journal article
PMID: 26939910
Record Identifier: 991031559002002976